Cell & Gene Therapy Manufacturing Services Market: Market Growth and Market Insights 2024-2032
The Cell & Gene Therapy Manufacturing Services Market Size was valued at USD 4.88 billion in 2022 and is expected to reach USD 12.85 billion by 2030, growing at a CAGR of 12.98% over the forecast period. This growth reflects increasing demand for personalized medicine, advances in genetic technologies, and a growing pipeline of cell and gene therapies in clinical trials.
Get Free Sample Report @ https://www.snsinsider.com/sample-request/1187
Market Description
Cell and gene therapy represent transformative approaches to treating and potentially curing diseases by targeting their root causes at the genetic level. The manufacturing of these advanced therapies requires highly specialized capabilities, infrastructure, and regulatory compliance. As pharmaceutical companies and biotechs increasingly invest in innovative therapies, demand for contract manufacturing services continues to rise, offering scalability, efficiency, and expertise.
Regional Analysis
- North America holds the largest market share due to robust healthcare infrastructure, heavy investments in R&D, and the presence of leading biotechnology firms.
- Europe is witnessing significant growth driven by favorable regulatory frameworks and collaborative research initiatives.
- Asia-Pacific is emerging rapidly, particularly in countries like China, Japan, and South Korea, fueled by expanding clinical trial activity and government support for biopharmaceutical innovation.
- Latin America and the Middle East & Africa are also gaining traction, albeit at a slower pace, as awareness and investment in advanced therapies increase.
Market Segmentation
By Therapy Type:
- Cell Therapy
- Gene Therapy
By Indication:
- Oncology
- Cardiovascular Diseases
- Neurological Disorders
- Others
By Mode:
- In-house Manufacturing
- Contract Manufacturing
By Scale:
- Preclinical
- Clinical
- Commercial
By Region:
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Key Players
- Cellular Therapeutics
- Lonza
- Bluebird Bio Inc.
- Thermo Fisher Scientific
- Samsung Biologics
- Boehringer Ingelheim
- Hitachi Chemical Co., Ltd.
- Takara Bio Inc.
- Catalent Inc.
- Miltenyi Biotec
- F. Hoffmann-La Roche Ltd
- Novartis AG
- Merck KGaA
- Wuxi Advanced Therapies and others.
Key Highlights
- Rapid advancements in gene editing tools such as CRISPR are transforming therapy development and accelerating commercialization timelines.
- Increasing FDA approvals and designations for cell and gene therapies are driving demand for scalable manufacturing solutions.
- Growing preference for outsourcing among biotech firms is expanding the market for contract development and manufacturing organizations (CDMOs).
- Strong investment activity in the life sciences sector continues to boost infrastructure and innovation.
- The oncology segment remains the dominant indication area, with a growing focus on rare and orphan diseases.
Future Scope
The future of the Cell & Gene Therapy Manufacturing Services Market looks promising, with a continued shift toward personalized and regenerative medicine. As the regulatory landscape becomes more defined and harmonized globally, manufacturing processes will evolve to become more standardized and efficient. Furthermore, the integration of digital technologies, automation, and AI in manufacturing workflows will enhance production capabilities and quality assurance. Strategic collaborations, mergers, and acquisitions are expected to shape the competitive landscape, enabling faster time-to-market and broader therapeutic access.
Conclusion
The Cell & Gene Therapy Manufacturing Services Market is poised for robust growth, driven by scientific innovation, rising therapeutic demand, and evolving healthcare priorities worldwide. As biopharmaceutical companies increasingly rely on specialized service providers for production and scalability, the market is set to play a pivotal role in shaping the future of advanced therapies.
Contact Us:
Jagney Dave - Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Other Related Reports:
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian